They didnt get US FDA approval, leading to more testing needed and therefore delays and cost blowouts...potential need for more capital raising.
Sales from Japan are poor, management have stuffed up there.
The didnt get TGA approval anywhere near there target time frame, and only just got reccommended for approval by TGA, however sales in Aus dont really mean much.
Sales in Europe have been slow.
Management is unstable and overpaid. Very poor.
I sold out of my position on TGA news, breaking even. Will consider buying back in down the future.
CCE Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
